dn-101
Cholestatic Liver Disease
Chulalongkorn UniversitySmall moleculePhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Cholestatic Liver Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
lum001 Mirum Pharmaceuticals, Inc. | Phase 3 | BB |
Tauroursodeoxycholic Beijing Trendful Kangjian Medical Information Consulting Limited Company | Phase 3 | B |
ERGOCALCIFEROLUM Chulalongkorn University | Phase 4 | B |
Saroglitazar Zydus Therapeutics Inc. | Phase 1 | CC |
Same molecule, other indications
dn-101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →